Sinonasal NUT carcinoma: A case report and literature review
Sinonasal NUT carcinoma (NC) is an exceptionally rare and fatal form of cancer, and the literature on this pathology is scarce. In this article, we report a case of ethmoidal NUT carcinoma, initially locally advanced then metastatic. Our case is the first to test immunotherapy and anti-EGFR in metas...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S277290602400373X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553685650341888 |
|---|---|
| author | Quentin Josset Merzouka Zidane-Marinnes Sylvie Giraud Camille landry Olivier Capitain |
| author_facet | Quentin Josset Merzouka Zidane-Marinnes Sylvie Giraud Camille landry Olivier Capitain |
| author_sort | Quentin Josset |
| collection | DOAJ |
| description | Sinonasal NUT carcinoma (NC) is an exceptionally rare and fatal form of cancer, and the literature on this pathology is scarce. In this article, we report a case of ethmoidal NUT carcinoma, initially locally advanced then metastatic. Our case is the first to test immunotherapy and anti-EGFR in metastatic sinonasal NUT carcinoma.This is a 47-year-old man diagnosed with ethmoidal NUT carcinoma cT4N0M0. Neoadjuvant chemotherapy (CT) was started with 5 cycles of TCF (Docetaxel 40 mg/m2 CDDP 40mg/m2 and 5FU 2000mg/m2), resulting in a discrete partial metabolic response, followed by radiotherapy (RT) (total dose, 70 Gy; 2 Gy × 35 Fractions). The PET scan re-evaluated at 2 months showed no tumor response and metastatic bone progression. In view of the epidermoid component of the histology, treatment with Nivolumab was introduced, but failed after 6 cycles, followed by Carboplatin (AUC 2), Paclitaxel (80mg/m2) 3 weeks out of 4 and Cetuximab (500mg/m2) twice monthly, but failed after 3 cycles, and finally Vinorebline (30mg) 3 times weekly, stopped early due to deterioration in general condition. The patient died 17 months after initial diagnosis. |
| format | Article |
| id | doaj-art-a2ff8a56518f44898bfc74684f3fbdca |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-a2ff8a56518f44898bfc74684f3fbdca2025-01-09T06:16:38ZengElsevierOral Oncology Reports2772-90602024-06-0110100527Sinonasal NUT carcinoma: A case report and literature reviewQuentin Josset0Merzouka Zidane-Marinnes1Sylvie Giraud2Camille landry3Olivier Capitain4Department of Radiotherapy, Institut de Cancérologie de l'ouest Angers, France; Corresponding author.Department Laboratory Medicine and Pathology, CHU Angers, FranceDepartment of Nuclear Medicine, Institut de Cancérologie de l'ouest Angers, FranceDepartment of Radiotherapy, Institut de Cancérologie de l'ouest Angers, FranceDepartment of Oncology, Institut de Cancérologie de l'ouest Angers, FranceSinonasal NUT carcinoma (NC) is an exceptionally rare and fatal form of cancer, and the literature on this pathology is scarce. In this article, we report a case of ethmoidal NUT carcinoma, initially locally advanced then metastatic. Our case is the first to test immunotherapy and anti-EGFR in metastatic sinonasal NUT carcinoma.This is a 47-year-old man diagnosed with ethmoidal NUT carcinoma cT4N0M0. Neoadjuvant chemotherapy (CT) was started with 5 cycles of TCF (Docetaxel 40 mg/m2 CDDP 40mg/m2 and 5FU 2000mg/m2), resulting in a discrete partial metabolic response, followed by radiotherapy (RT) (total dose, 70 Gy; 2 Gy × 35 Fractions). The PET scan re-evaluated at 2 months showed no tumor response and metastatic bone progression. In view of the epidermoid component of the histology, treatment with Nivolumab was introduced, but failed after 6 cycles, followed by Carboplatin (AUC 2), Paclitaxel (80mg/m2) 3 weeks out of 4 and Cetuximab (500mg/m2) twice monthly, but failed after 3 cycles, and finally Vinorebline (30mg) 3 times weekly, stopped early due to deterioration in general condition. The patient died 17 months after initial diagnosis.http://www.sciencedirect.com/science/article/pii/S277290602400373XSinonasalNUT carcinomaImmunotherapyCetuximab |
| spellingShingle | Quentin Josset Merzouka Zidane-Marinnes Sylvie Giraud Camille landry Olivier Capitain Sinonasal NUT carcinoma: A case report and literature review Oral Oncology Reports Sinonasal NUT carcinoma Immunotherapy Cetuximab |
| title | Sinonasal NUT carcinoma: A case report and literature review |
| title_full | Sinonasal NUT carcinoma: A case report and literature review |
| title_fullStr | Sinonasal NUT carcinoma: A case report and literature review |
| title_full_unstemmed | Sinonasal NUT carcinoma: A case report and literature review |
| title_short | Sinonasal NUT carcinoma: A case report and literature review |
| title_sort | sinonasal nut carcinoma a case report and literature review |
| topic | Sinonasal NUT carcinoma Immunotherapy Cetuximab |
| url | http://www.sciencedirect.com/science/article/pii/S277290602400373X |
| work_keys_str_mv | AT quentinjosset sinonasalnutcarcinomaacasereportandliteraturereview AT merzoukazidanemarinnes sinonasalnutcarcinomaacasereportandliteraturereview AT sylviegiraud sinonasalnutcarcinomaacasereportandliteraturereview AT camillelandry sinonasalnutcarcinomaacasereportandliteraturereview AT oliviercapitain sinonasalnutcarcinomaacasereportandliteraturereview |